EL7.AI
StocksMediumUpdated•Originally published 29 September 2026•Updated 29 September 2026•
1 min read

Eli Lilly's Zepbound Outperforms Wegovy HD in Obesity Weight Loss Trials

Key Facts

1Eli Lilly announced that higher doses of its drug Zepbound outperformed Novo Nordisk's Wegovy HD in clinical comparisons.

Eli Lilly announced that higher doses of its drug Zepbound outperformed Novo Nordisk's Wegovy HD in weight loss clinical comparisons. Seeking Alpha reported that the company released this data to strengthen its market position within the highly competitive GLP-1 obesity treatment sector.

LLY closed at $1184.78 on September 28, 2026, as the company continues to present efficacy data for its flagship product. During that session, the stock reached a high of $1194.09 and a low of $1172.56.

Latest Updates · 1

  1. Notable·

    Update: Eli Lilly announced on September 29, 2026, that a new experimental drug helped adults with type 2 diabetes and obesity lose nearly 21% of their body weight. These results emerged from a late-stage clinical trial, further expanding the company's metabolic treatment portfolio.

Open on chart